企業プロフィール
Zevra 株価・ニュース・カタリスト
- ティッカー:
- ZVRA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
11.87 USD (-0.17%)
終値
最終更新: 2026年8月21日
643M USD
時価総額
株価変動の要因
The latest monitored company update is “Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
企業概要
Rare-Disease Commercial Platform
Zevra Therapeutics is a commercial-stage company focused on therapies for rare diseases. Its operating model combines direct commercialization, global patient-access programs and development of treatments for small, underserved populations.
MIPLYFFA
MIPLYFFA, or arimoclomol, is FDA approved with miglustat for neurological manifestations of Niemann-Pick disease type C in patients two years and older. Zevra also operates a global expanded-access program and has submitted a European marketing application.
OLPRUVA
OLPRUVA is an approved formulation of sodium phenylbutyrate for certain urea-cycle disorders, giving Zevra a second commercial product in inherited metabolic disease.
Celiprolol
Celiprolol is an investigational treatment for vascular Ehlers-Danlos syndrome. The event-driven Phase 3 DiSCOVER trial is being conducted under an FDA Special Protocol Assessment.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。